Perspective
Agency Overreach Leaves Patients Untreated
June 10, 2025
Featured Experts: Joseph Grogan, JD
Research
All Research Featured Research
Perspective
The Biotech Industry Needs to Make Its Case for Bold Change to the White House
May 7, 2025
Featured Experts: Joseph Grogan, JD
Perspective
Medicare Should Cover Wegovy — But Not Negotiate Its Price
January 17, 2025
Featured Experts: Joseph Grogan, JD
Perspective
Government Needs to Do More to Ensure Obesity Drug Safety
December 16, 2024
Featured Experts: Joseph Grogan, JD
Evidence Base
Reforming Health Policy to Expand Cognitive Screening
December 12, 2024
Featured Experts: Joseph Grogan, JD
Perspective
Congress Must Roll Back a Key Anti-Innovation Biden-Harris Policy
September 21, 2024
Featured Experts: Joseph Grogan, JD
Perspective
Access to New Alzheimer’s Treatments Bogged Down by Medicare Policy
June 17, 2024
Featured Experts: Joseph Grogan, JD
Comment Letter
Response to Sen. Cassidy’s Request for Information on Improving Americans’ Access to Gene Therapies
January 19, 2024
Featured Experts: Darius Lakdawalla, PhD, Joseph Grogan, JD, Stephanie Hedt, MPP, Barry Liden, JD, Erin Trish, PhD, Karen Van Nuys, PhD
Perspective
The Inflation Reduction Act’s Harms Go Beyond Drug Pricing — They’re Threatening Your Medicare
December 23, 2023
Featured Experts: Joseph Grogan, JD
Perspective
Congress Wants a Better Value. So Why Are They Eliminating Performance Based Payment?
October 12, 2023
Featured Experts: Joseph Grogan, JD
Comment Letter
Comments to CMS on Proposed Guidance for Coverage with Evidence Development
August 25, 2023
Featured Experts: Alice Chen, PhD, Joseph Grogan, JD, Mireille Jacobson, PhD, Geoffrey Joyce, PhD, Darius Lakdawalla, PhD, Barry Liden, JD, Eugene Lin, MD, MS, Karen Van Nuys, PhD, William Padula, PhD, Alison Sexton Ward, PhD, Julie Zissimopoulos, PhD
Perspective
Beware of the Government’s Healthcare ‘Truth’ Peddlers
August 22, 2023
Featured Experts: Joseph Grogan, JD
Perspective
The Agency Keeping Alzheimer’s Drugs from Patients
May 5, 2023
Featured Experts: Joseph Grogan, JD
Perspective
Medicare’s ‘Coverage With Evidence Development’: A Barrier to Patient Access and Innovation
May 1, 2023
Featured Experts: Joseph Grogan, JD
Comment Letter
Comments to CMS on the Inflation Reduction Act’s Drug Price Negotiation Program
April 17, 2023
Featured Experts: Dana Goldman, PhD, Charles E. Phelps, PhD, Darius Lakdawalla, PhD, Joseph Grogan, JD, Karen Van Nuys, PhD, Barry Liden, JD, William Padula, PhD
White Paper
Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market
April 13, 2023
Featured Experts: Dana Goldman, PhD, Joseph Grogan, JD, Darius Lakdawalla, PhD, Barry Liden, JD, Erin Trish, PhD
Perspective
Biden Administration Must Follow the Science By Expanding Access to Alzheimer’s Innovation
March 16, 2023
Featured Experts: Joseph Grogan, JD
Perspective
The Inflation Reduction Act Is Already Killing Potential Cures
November 3, 2022
Featured Experts: Joseph Grogan, JD
Evidence Base
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
October 21, 2022
Featured Experts: Joseph Grogan, JD
Comment Letter
Comments on AHRQ Analysis of Requirements for Coverage with Evidence Development
September 28, 2022
Featured Experts: Dana Goldman, PhD, William Padula, PhD, Joseph Grogan, JD, Barry Liden, JD